Treatment with momelotinib yields clinically significant improvements, when compared with danazol, for
patients with myelofibrosis, according to a study published in The Lancet. Srdan Verstovsek, MD, and colleagues conducted a randomized phase 3 study at 107 sites across 21 countries involving adults with a confirmed diagnosis of primary myelofibrosis or post-polycythemia vera or post-essential thrombocythemia myelofibrosis. Patients were randomly assigned to receive momelotinib plus danazol placebo or danazol plus momelotinib placebo (130 and 65 patients, respectively). A significantly greater proportion of patients in the momelotinib group versus the danazol group reported a 50% or greater reduction in total symptom score (25% vs 9%, respectively). Hematologic abnormalities by laboratory values were the most frequent grade 3 or higher treatment-emergent adverse events with momelotinib and danazol, including anemia (61% and 75%, respectively) and thrombocytopenia (28% and 26%, respectively). Acute kidney injury and pneumonia were the most frequent non-hematologic grade 3 or higher treatment-emergent adverse events with momelotinib and danazol (3% vs 9%; 2% vs 9%, respectively).
